The success of MenAfriVac has paved the way for the development of vaccines against other serogroups of meningococcal disease. There is ongoing research to develop multivalent vaccines that can protect against multiple serogroups, thereby providing broader protection. The experience gained from the MenAfriVac campaign also offers valuable lessons for the implementation of other vaccination programs in low-resource settings.
